Citation Tools

Download PDFPDF
559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)

Download to a citation manager

Cite this article as:
Hamilton EP, Papadopoulos KP, Barve M, et al
559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)